Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction
- 22 November 2018
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 44 (3) , 836-844
Abstract
Positron emission tomography (PET)/magnetic resonance imaging (MRI) is a new modality that has showed promising results for various clinical indications. Currently, evaluation of neoadjuvant therapy (NT) among patients with adenocarcinoma of the esophagogastric junction has primarily been reserved for PET/computed tomography. Our aim was to evaluate if early response evaluation by PET/MRI is a feasible method to predict resectability.Keywords
Funding Information
- Kræftens Bekæmpelse (R136-A8486-15-S7)
This publication has 29 references indexed in Scilit:
- A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic FactorsAnnals of Surgical Oncology, 2014
- Response to chemotherapy in gastric adenocarcinoma with diffusion‐weighted MRI and 18F‐FDG‐PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression gradeJournal of Magnetic Resonance Imaging, 2013
- PET/MRI in cancer patients: first experiences and vision from CopenhagenMagnetic Resonance Materials in Physics, Biology and Medicine, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic DiagnosesJournal of Nuclear Medicine, 2012
- Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancerEuropean Radiology, 2010
- Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic DecisionsSeminars in Nuclear Medicine, 2009
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialThe Lancet Oncology, 2007
- Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric JunctionJournal of Clinical Oncology, 2006
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006